The global Varicella Vaccination market size was valued at US$ 5009 million in 2024 and is forecast to a readjusted size of USD 8327 million by 2031 with a CAGR of 7.6% during review period.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Varicella Vaccination market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Varicella Vaccination market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Varicella Vaccination market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Varicella Vaccination market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Varicella Vaccination market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Varicella Vaccination
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Varicella Vaccination market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, BCHT, Shanghai Institute, GSK, Keygen, Green Cross, Biken, Shanghai Rongsheng Biotech, Changsheng, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Varicella Vaccination market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Monovalent Vaccine
Combination Vaccine
麻豆原创 segment by Application
Children
Adults
Major players covered
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Varicella Vaccination product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Varicella Vaccination, with price, sales quantity, revenue, and global market share of Varicella Vaccination from 2020 to 2025.
Chapter 3, the Varicella Vaccination competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Varicella Vaccination breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Varicella Vaccination market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Varicella Vaccination.
Chapter 14 and 15, to describe Varicella Vaccination sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Varicella Vaccination Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Monovalent Vaccine
1.3.3 Combination Vaccine
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Varicella Vaccination Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Children
1.4.3 Adults
1.5 Global Varicella Vaccination 麻豆原创 Size & Forecast
1.5.1 Global Varicella Vaccination Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Varicella Vaccination Sales Quantity (2020-2031)
1.5.3 Global Varicella Vaccination Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Varicella Vaccination Product and Services
2.1.4 Merck Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Merck Recent Developments/Updates
2.2 BCHT
2.2.1 BCHT Details
2.2.2 BCHT Major Business
2.2.3 BCHT Varicella Vaccination Product and Services
2.2.4 BCHT Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 BCHT Recent Developments/Updates
2.3 Shanghai Institute
2.3.1 Shanghai Institute Details
2.3.2 Shanghai Institute Major Business
2.3.3 Shanghai Institute Varicella Vaccination Product and Services
2.3.4 Shanghai Institute Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Shanghai Institute Recent Developments/Updates
2.4 GSK
2.4.1 GSK Details
2.4.2 GSK Major Business
2.4.3 GSK Varicella Vaccination Product and Services
2.4.4 GSK Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 GSK Recent Developments/Updates
2.5 Keygen
2.5.1 Keygen Details
2.5.2 Keygen Major Business
2.5.3 Keygen Varicella Vaccination Product and Services
2.5.4 Keygen Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Keygen Recent Developments/Updates
2.6 Green Cross
2.6.1 Green Cross Details
2.6.2 Green Cross Major Business
2.6.3 Green Cross Varicella Vaccination Product and Services
2.6.4 Green Cross Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Green Cross Recent Developments/Updates
2.7 Biken
2.7.1 Biken Details
2.7.2 Biken Major Business
2.7.3 Biken Varicella Vaccination Product and Services
2.7.4 Biken Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Biken Recent Developments/Updates
2.8 Shanghai Rongsheng Biotech
2.8.1 Shanghai Rongsheng Biotech Details
2.8.2 Shanghai Rongsheng Biotech Major Business
2.8.3 Shanghai Rongsheng Biotech Varicella Vaccination Product and Services
2.8.4 Shanghai Rongsheng Biotech Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Shanghai Rongsheng Biotech Recent Developments/Updates
2.9 Changsheng
2.9.1 Changsheng Details
2.9.2 Changsheng Major Business
2.9.3 Changsheng Varicella Vaccination Product and Services
2.9.4 Changsheng Varicella Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Changsheng Recent Developments/Updates
3 Competitive Environment: Varicella Vaccination by Manufacturer
3.1 Global Varicella Vaccination Sales Quantity by Manufacturer (2020-2025)
3.2 Global Varicella Vaccination Revenue by Manufacturer (2020-2025)
3.3 Global Varicella Vaccination Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Varicella Vaccination by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Varicella Vaccination Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Varicella Vaccination Manufacturer 麻豆原创 Share in 2024
3.5 Varicella Vaccination 麻豆原创: Overall Company Footprint Analysis
3.5.1 Varicella Vaccination 麻豆原创: Region Footprint
3.5.2 Varicella Vaccination 麻豆原创: Company Product Type Footprint
3.5.3 Varicella Vaccination 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Varicella Vaccination 麻豆原创 Size by Region
4.1.1 Global Varicella Vaccination Sales Quantity by Region (2020-2031)
4.1.2 Global Varicella Vaccination Consumption Value by Region (2020-2031)
4.1.3 Global Varicella Vaccination Average Price by Region (2020-2031)
4.2 North America Varicella Vaccination Consumption Value (2020-2031)
4.3 Europe Varicella Vaccination Consumption Value (2020-2031)
4.4 Asia-Pacific Varicella Vaccination Consumption Value (2020-2031)
4.5 South America Varicella Vaccination Consumption Value (2020-2031)
4.6 Middle East & Africa Varicella Vaccination Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Varicella Vaccination Sales Quantity by Type (2020-2031)
5.2 Global Varicella Vaccination Consumption Value by Type (2020-2031)
5.3 Global Varicella Vaccination Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Varicella Vaccination Sales Quantity by Application (2020-2031)
6.2 Global Varicella Vaccination Consumption Value by Application (2020-2031)
6.3 Global Varicella Vaccination Average Price by Application (2020-2031)
7 North America
7.1 North America Varicella Vaccination Sales Quantity by Type (2020-2031)
7.2 North America Varicella Vaccination Sales Quantity by Application (2020-2031)
7.3 North America Varicella Vaccination 麻豆原创 Size by Country
7.3.1 North America Varicella Vaccination Sales Quantity by Country (2020-2031)
7.3.2 North America Varicella Vaccination Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Varicella Vaccination Sales Quantity by Type (2020-2031)
8.2 Europe Varicella Vaccination Sales Quantity by Application (2020-2031)
8.3 Europe Varicella Vaccination 麻豆原创 Size by Country
8.3.1 Europe Varicella Vaccination Sales Quantity by Country (2020-2031)
8.3.2 Europe Varicella Vaccination Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Varicella Vaccination Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Varicella Vaccination Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Varicella Vaccination 麻豆原创 Size by Region
9.3.1 Asia-Pacific Varicella Vaccination Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Varicella Vaccination Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Varicella Vaccination Sales Quantity by Type (2020-2031)
10.2 South America Varicella Vaccination Sales Quantity by Application (2020-2031)
10.3 South America Varicella Vaccination 麻豆原创 Size by Country
10.3.1 South America Varicella Vaccination Sales Quantity by Country (2020-2031)
10.3.2 South America Varicella Vaccination Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Varicella Vaccination Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Varicella Vaccination Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Varicella Vaccination 麻豆原创 Size by Country
11.3.1 Middle East & Africa Varicella Vaccination Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Varicella Vaccination Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Varicella Vaccination 麻豆原创 Drivers
12.2 Varicella Vaccination 麻豆原创 Restraints
12.3 Varicella Vaccination Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Varicella Vaccination and Key Manufacturers
13.2 Manufacturing Costs Percentage of Varicella Vaccination
13.3 Varicella Vaccination Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Varicella Vaccination Typical Distributors
14.3 Varicella Vaccination Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
听
听
*If Applicable.
